Literature DB >> 28295472

Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma.

Nicholas J Short1, Hagop M Kantarjian2, Heidi Ko3, Joseph D Khoury4, Farhad Ravandi2, Deborah A Thomas2, Guillermo Garcia-Manero2, Maria Khouri2, Jorge E Cortes2, William G Wierda2, Srdan Verstovsek2, Zeev Estrov2, Alessandra Ferrajoli2, Philip A Thompson2, Sherry Pierce2, Susan M O'Brien5, Elias Jabbour2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28295472      PMCID： PMC5828013          DOI： 10.1002/ajh.24720

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  10 in total

Review 1.  Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?

Authors:  Deborah A Thomas; Susan O'Brien; Stefan Faderl; John T Manning; Jorge Romaguera; Luis Fayad; Fredrick Hagemeister; Jeffrey Medeiros; Jorge Cortes; Hagop Kantarjian
Journal:  Curr Hematol Malig Rep       Date:  2011-03       Impact factor: 3.952

2.  Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective "Lymphomes Malins B" protocols. A Société Française des Cancers de l'Enfant study.

Authors:  Anne Jourdain; Anne Auperin; Véronique Minard-Colin; Nathalie Aladjidi; Josef Zsiros; Carole Coze; Virginie Gandemer; Yves Bertrand; Guy Leverger; Christophe Bergeron; Jean Michon; Catherine Patte
Journal:  Haematologica       Date:  2015-02-27       Impact factor: 9.941

3.  Outcome of childhood relapsed or refractory mature B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia.

Authors:  Parameswaran Anoop; Sushama Sankpal; Charles Stiller; Sanjay Tewari; Donna L Lancaster; Komel Khabra; Mary M Taj
Journal:  Leuk Lymphoma       Date:  2012-04-23

4.  How I treat Burkitt lymphoma in adults.

Authors:  Caron Jacobson; Ann LaCasce
Journal:  Blood       Date:  2014-09-25       Impact factor: 22.113

5.  Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial.

Authors:  Vincent Ribrag; Serge Koscielny; Jacques Bosq; Thibaut Leguay; Olivier Casasnovas; Luc-Mathieu Fornecker; Christian Recher; Hervé Ghesquieres; Franck Morschhauser; Stéphane Girault; Steven Le Gouill; Mario Ojeda-Uribe; Clara Mariette; Jerome Cornillon; Guillaume Cartron; Veronique Verge; Catherine Chassagne-Clément; Hervé Dombret; Bertrand Coiffier; Thierry Lamy; Hervé Tilly; Gilles Salles
Journal:  Lancet       Date:  2016-04-11       Impact factor: 79.321

6.  Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.

Authors:  Deborah A Thomas; Stefan Faderl; Susan O'Brien; Carlos Bueso-Ramos; Jorge Cortes; Guillermo Garcia-Manero; Francis J Giles; Srdan Verstovsek; William G Wierda; Sherry A Pierce; Jianqin Shan; Mark Brandt; Fredrick B Hagemeister; Michael J Keating; Fernando Cabanillas; Hagop Kantarjian
Journal:  Cancer       Date:  2006-04-01       Impact factor: 6.860

Review 7.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors:  Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

Review 8.  Burkitt's lymphoma: clinicopathologic features and differential diagnosis.

Authors:  Judith A Ferry
Journal:  Oncologist       Date:  2006-04

9.  Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma--outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation.

Authors:  J W Sweetenham; R Pearce; G Taghipour; D Blaise; C Gisselbrecht; A H Goldstone
Journal:  J Clin Oncol       Date:  1996-09       Impact factor: 44.544

10.  Clinical outcome of relapsed or refractory burkitt lymphoma and mature B-cell lymphoblastic leukemia in children and adolescents.

Authors:  Hyery Kim; Eun Sil Park; Soo Hyun Lee; Hong Hoe Koo; Hyo Sun Kim; Chuhl Joo Lyu; So Eun Jun; Young Tak Lim; Hee Jo Baek; Hoon Kook; Ji Won Lee; Hyoung Jin Kang; Kyung Duk Park; Hee Young Shin; Hyeo Seop Ahn
Journal:  Cancer Res Treat       Date:  2014-07-21       Impact factor: 4.679
  10 in total
  9 in total

Review 1.  Burkitt lymphoma: bridging the gap between advances in molecular biology and therapy.

Authors:  Adam S Zayac; Adam J Olszewski
Journal:  Leuk Lymphoma       Date:  2020-04-07

2.  Reply to M. Hertzberg et al.

Authors:  Mark Roschewski; Kieron Dunleavy; Wyndham H Wilson
Journal:  J Clin Oncol       Date:  2020-09-15       Impact factor: 44.544

3.  Durable remissions in two adult patients with Burkitt lymphoma following anti-CD19 CAR T-cell therapy: a single center experience.

Authors:  Samantha J Seitter; Paul H McClelland; Mark A Ahlman; Stephanie L Goff; James C Yang; Lori McIntyre; Steven A Rosenberg; James N Kochenderfer; Jennifer N Brudno
Journal:  Leuk Lymphoma       Date:  2022-06-09

4.  Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma.

Authors:  Jiaying Wu; Yang Cao; Qi Zhang; Wanying Liu; Xiaoxi Zhou; Xi Ming; Fankai Meng; Yicheng Zhang; Chunrui Li; Liang Huang; Jia Wei; Miao Zheng; Shangkun Zhang; Tongcun Zhang; Xiaojian Zhu; Na Wang; Jue Wang; Gaoxiang Wang; Jianfeng Zhou; Bo Liu; Yi Xiao
Journal:  Front Immunol       Date:  2022-05-20       Impact factor: 8.786

5.  Favourable outcomes for high-risk Burkitt lymphoma patients (IPI 3-5) treated with rituximab plus CODOX-M/IVAC: Results of a phase 2 UK NCRI trial.

Authors:  Elizabeth H Phillips; Catherine Burton; Amy A Kirkwood; Sharon Barrans; Anthony Lawrie; Simon Rule; Russell Patmore; Ruth Pettengell; Kirit M Ardeshna; Silvia Montoto; Shankara Paneesha; Laura Clifton-Hadley; David C Linch; Andrew K McMillan
Journal:  EJHaem       Date:  2020-04-29

6.  Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study.

Authors:  Adam S Zayac; Andrew M Evens; Alexey Danilov; Stephen D Smith; Deepa Jagadeesh; Lori A Leslie; Catherine Wei; Seo-Hyun Kim; Seema Naik; Suchitra Sundaram; Nishitha Reddy; Umar Farooq; Vaishalee P Kenkre; Narendranath Epperla; Kristie A Blum; Nadia Khan; Daulath Singh; Juan P Alderuccio; Amandeep Godara; Maryam Sarraf Yazdy; Catherine Diefenbach; Emma Rabinovich; Gaurav Varma; Reem Karmali; Yusra Shao; Asaad Trabolsi; Madelyn Burkart; Peter Martin; Sarah Stettner; Ayushi Chauhan; Yun Kyong Choi; Allandria Straker-Edwards; Andreas Klein; Michael C Churnetski; Kirsten M Boughan; Stephanie Berg; Bradley M Haverkos; Victor M Orellana-Noia; Christopher D'Angelo; David A Bond; Seth M Maliske; Ryan Vaca; Gabriella Magarelli; Amy Sperling; Max J Gordon; Kevin A David; Malvi Savani; Paolo Caimi; Manali Kamdar; Matthew A Lunning; Neil Palmisiano; Parameswaran Venugopal; Craig A Portell; Veronika Bachanova; Tycel Phillips; Izidore S Lossos; Adam J Olszewski
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

7.  Unusually swift response of relapsed Burkitt leukemia to R-DHAP.

Authors:  Dennis Christoph Harrer; Alexander Denk; Felix Keil; Karin Menhart; Stephanie Mayer; Daniel Wolff; Matthias Edinger; Wolfgang Herr; Matthias Grube
Journal:  EJHaem       Date:  2022-06-13

8.  Late recurrence of Burkitt's lymphoma in the jaw: numb chin syndrome as the only symptom.

Authors:  Bernar Monteiro Benites; Wanessa Miranda-Silva; André Caroli Rocha; Ula Lindoso Passos; Felipe Paiva Fonseca; Celso Arrais Rodrigues da Silva; Eduardo Rodrigues Fregnani
Journal:  Autops Case Rep       Date:  2020-12-08

Review 9.  Novel Biological Insights and New Developments in Management of Burkitt Lymphoma and High-Grade B-Cell Lymphoma.

Authors:  Coen J Lap; Samah Nassereddine; Kieron Dunleavy
Journal:  Curr Treat Options Oncol       Date:  2021-06-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.